MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

95.05
+0.78
+0.83%
Closed 16:01 09/23 EDT
OPEN
94.28
PREV CLOSE
94.27
HIGH
95.54
LOW
93.51
VOLUME
406.10K
TURNOVER
--
52 WEEK HIGH
120.27
52 WEEK LOW
84.77
MARKET CAP
9.00B
P/E (TTM)
25.54
1D
5D
1M
3M
1Y
5Y
Biogen, Sage are new buys as Needham initiates coverage on neuro-focused stocks
Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) have been granted buy ratings at Needham as the firm initiated the coverage on companies focused on neurological diseases despite hurdles for therapeutic development
Seekingalpha · 23h ago
Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 79%
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see...
Simply Wall St. · 3d ago
Neurocrine Biosciences To Present New INGREZZA (valbenazine) And ONGENTYS (opicapone) Data At MDS Virtual Congress 2021
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the International Parkinson
Benzinga · 09/10 13:25
Neurocrine Biosciences to Present New INGREZZA® (valbenazine) and ONGENTYS® (opicapone) Data at the MDS Virtual Congress 2021
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the International Parkinson and Movement Disorder Society's (MDS) Virtual...
PR Newswire · 09/10 13:23
BRIEF-Xenon Says Collaboration With Neurocrine Achieves $10.0 Mln Regulatory Milestone
reuters.com · 09/08 13:00
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone with the app...
GlobeNewswire · 09/08 12:30
--Street Color: Xenon Pharmaceuticals Gets $10 Mln Milestone in Neurocrine Biosciences Pact: Bloomberg
MT Newswires · 09/08 09:10
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following virtual investor conferences:
PR Newswire - PRF · 09/02 20:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBIX. Analyze the recent business situations of Neurocrine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 25 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBIX stock price target is 122.19 with a high estimate of 163.00 and a low estimate of 99.00.
EPS
Institutional Holdings
Institutions: 579
Institutional Holdings: 102.66M
% Owned: 108.46%
Shares Outstanding: 94.65M
TypeInstitutionsShares
Increased
162
3.84M
New
47
1.67M
Decreased
127
8.11M
Sold Out
51
1.02M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
William Rastetter
Chief Executive Officer/Director
Kevin Gorman
Chief Financial Officer
Matthew Abernethy
Chief Human Resource Officer
Julie Cooke
Other
Eric Benevich
Other
David Boyer
Other
Kyle Gano
Other
Dimitri Grigoriadis
Other
Malcolm Lloyd-Smith
Other
Eiry Roberts
Secretary
Darin Lippoldt
Director
Johanna Mercier
Independent Director
Gary Lyons
Independent Director
George Morrow
Independent Director
Leslie Norwalk
Independent Director
Richard Pops
Independent Director
Shalini Sharp
Independent Director
Stephen Sherwin
No Data
  • All
  • Financials
  • Insiders
More
About NBIX
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.